ISSN 1006-298X      CN 32-1425/R

导航

肾脏病与透析肾移植杂志 ›› 2025, Vol. 34 ›› Issue (3): 240-244.DOI: 10.3969 / j.issn.1006⁃298X.2025.03.007

• 论著 • 上一篇    下一篇

动静脉内瘘经皮腔内血管成形术镇痛药物的选择

  

  • 出版日期:2025-06-28 发布日期:2025-06-26

Selection of analgesic drugs for arteriovenous fistula percutaneous transluminal angioplasty

  • Online:2025-06-28 Published:2025-06-26

摘要: 目的:探讨不同镇痛药物对动静脉内瘘经皮腔内血管成形术( PTA) 术中疼痛的缓解程度,以期指导PTA 术前镇痛药物的选择。 方法:回顾性收集 2022 1 月至 2023 1 月在徐州医科大学附属淮海医院行动静脉内瘘 PTA 治疗的患者 150 例,根据镇痛方式分为三组:对照组( 50 例,术前未用镇痛药物)、术前塞来昔布组( 50 例) 和术前吗啡组( 50 例),术后使用视觉模拟量表( VAS) 及疼痛数字评分量表( NRS) 评估患者手术过程中的疼痛程度,并观察患者术后随访 1 月、3 月、6 月、9 月、12 月的动静脉内瘘的通畅情况。 结果:对照组、塞来昔布组、吗啡组的 VAS 的中位疼痛评分分别为 73,10)、5( 1,10)、3( 0,6)( F = 61.89,P<0.05)。  此外,三组 NRS 中位疼痛评分为 72,10)、5( 1,10)、3( 0,6)( F = 54.79,P<0.05)。  对照组术后 1 月、3 月、6 月、9 月、12 月的动静脉内瘘的通畅率为 94%、88%、78%、70%、58%;塞来昔布组分别为 92%、88%、80%、68%、60%;吗啡组分别为 94%、86%、76%、68%、62%。  三组在各时间点的动静脉初级内瘘通畅率均无统计学差异。    结论:术前应用塞来昔布和吗啡注射液均能有效缓解血液透析患者行动静脉内瘘 PTA  中的疼痛,吗啡注射液镇痛效果优于塞来昔布,且未影响初级动静脉内瘘通畅率。

关键词: 血液透析, 动静脉内瘘, 经皮腔内血管成形术, 镇痛剂

Abstract: Objective:To evaluate the efficacy of different analgesic drugs in alleviating pain during percutaneous transluminal angioplasty ( PTAof arteriovenous fistulaswith the goal of guiding analgesic selection for PTA procedures. Methodology:This  retrospective  study  included  patients  who  underwent  arteriovenous  fistula  PTA  at  Huaihai  HospitalXuzhou Medical University,  between  January  2022  to  January  2023.  A  total  of  150  patients  were  categorized  into  three groups based on the analgesic strategy: the Control group n = 50no preoperative analgesics), the Celecoxib group n = 50received preoperative celecoxib), and the  Morphine  group  n = 50,  received  preoperative  morphine).  Pain  intensity during the  procedure  was  assessed  using  the  Visual  Analogue  Scale  ( VAS)  and  the  Numeric  Rating  Scale  NRS). Arteriovenous fistula patency was evaluated at 1, 369and 12 months postoperatively.    Results:The median VAS pain scores were 7 ( range 3- 10) in the control group, 5 ( range 1- 10) in the celecoxib group, and 3 ( range 0- 6) in the morphine groupshowing statistically significant differences F = 61.89P<0.05). Similarly, the median NRS scores were 7 range 2-10)  in the control group5 range 1-10)  in the celecoxib groupand 3 range 0-6)  in the morphine grouprespectivelyalso with  significant  differences  F = 54.79,  P < 0.05).  The  fistula  patency  rates  at  1,  3,  6,  9,  and  12 months were 94%88%,  78%,  70%  in  control  group92%,  88%,  80%,  68%  in  celecpxib  group,  and  94%,  86%76%68%  in morphine group. No significant differences in patency rates were observed among groups at any time point. Conclusion: Preoperative   administration   of   either   celecoxib   or   morphine   effectively   reduces   pain   during   PTA   of arteriovenous fistulas in  hemodialysis  patients.  Morphine  provides  superior  analgesia  compared  with  celecoxib.  Moreover, mophine and celecoxib did not affect the patency rate of primary arteriovenous fistul.

Key words: hemodialysis,  arteriovenous fistula,  percutaneous trasluminal angioplasty,  analgesics